Simplify Logo

Full-Time

ML Infrastructure Engineer – Senior / Staff / Principal

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

Hardware
AI & Machine Learning
Biotechnology
Healthcare

Senior, Expert

Burlingame, CA, USA

Category
DevOps & Infrastructure
Platform Engineering
Requirements
  • Strong engineer who constantly strives for technical excellence. You can write clean code and have a deep understanding of the codebases you work in.
  • Deeply experienced with distributed training and inference of large models on GPU clusters and some of the core libraries and frameworks we use: Pytorch, Pytorch Lightning, Pytorch Geometric, and Ray.
  • Independent thinker with a strong sense of ownership and capability of engineering robust systems from first-principles-based conceptualization to state-of-the-art realization.
  • Curious, problem-oriented thinker who is excited to dive deep into the emerging field at the intersection of AI, physics, chemistry, and biology and make foundational contributions and discoveries (no previous experience in anything but ML necessary).
Responsibilities
  • Lead engineering efforts focused on continuous improvement of the AI platform, focused on rapid build out and iteration on scalable and robust distributed infrastructure for ML training, inference, and evaluation.
  • Support model training and deployment across multiple clusters and multiple clouds, optimizing for throughput and cost.
  • Optimizing efficiency of ML models and other workloads in terms of latency, throughput, memory consumption, etc. (e.g., via GPU performance engineering), pushing the limits of what’s possible with the current hardware.
  • Define the long-term vision for Genesis’ ML platform.
  • Have the opportunity to mentor and guide more junior members of our technical team as well as research interns, fostering an environment of growth and innovation.

Genesis Therapeutics focuses on accelerating the development of new medicines using artificial intelligence in the drug discovery sector. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables the exploration of new chemical spaces and the discovery of novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide its AI-driven drug discovery services. The company generates revenue through upfront payments and potential future earnings based on the success of the drugs developed through its platform. Genesis Therapeutics aims to transform the drug discovery process and bring critical new medicines to market.

Company Stage

Series B

Total Funding

$256.1M

Headquarters

Burlingame, California

Founded

2019

Growth & Insights
Headcount

6 month growth

23%

1 year growth

32%

2 year growth

128%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recognition as a 'Fierce 15' company and one of America's most promising AI companies highlights Genesis Therapeutics' industry leadership and innovation.
  • The $200M Series B funding will enable the company to advance its AI-enabled pipeline into clinical development, potentially leading to groundbreaking new treatments.
  • Partnerships with industry giants like NVIDIA and Eli Lilly provide substantial opportunities for growth and collaboration.

What critics are saying

  • The highly competitive biotech and AI-driven drug discovery sectors may pose challenges in maintaining a unique market position.
  • Dependence on strategic partnerships and funding rounds could impact financial stability if future deals or investments do not materialize.

What makes Genesis Therapeutics unique

  • Genesis Therapeutics leverages a unique combination of 3D spatial graph modeling and advanced molecular simulation, setting it apart from traditional drug discovery methods.
  • Their AI platform, GEMS, is capable of generating novel drug-like molecules and making rapid, accurate predictions for challenging targets, which is a significant competitive advantage.
  • Strategic partnerships with major pharmaceutical companies like Eli Lilly and significant funding rounds, including a $200M Series B, underscore their strong market position.

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program